Advertisement

Die Onkologie pp 1267-1309 | Cite as

Maligne Hodentumoren

  • H. J. Schmoll

Zusammenfassung

Hodentumoren sind zu 98% Keimzelltumoren, der Rest sind Tumoren des Stroma- und Stützgewebes. In diesem Kapitel werden beide Gruppen getrennt dargestellt. Maligne Keimzelltumoren stellen die häufigsten bösartigen Tumoren junger Männer zwischen 20 und 35 Jahren dar. Bei einem Lebenszeitrisiko von 1: 500 (Davies 1981), an einem Keimzelltumor zu erkranken, bedeutete die Erkrankung vor der Ara cisplatinhaltiger Polychemotherapien wegen der hohen Malignität und Metastasierungsrate zugleich auch die häufigste Krebstodesursache von Männern in dieser Altersgruppe. Durch die Einführung der cisplatinhaltigen Polychemotherapien Ende der siebziger Jahre konnte die Heilungsrate auf insgesamt 90–95% gesteigert werden (Schmoll 1999a). Damit handelt es sich um den derzeit am besten behandelbaren Tumor im Erwachsenenalter mit der höchsten Heilungsrate.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abell A (1994) Organic food and sperm counts in men. Food Magazine 25:Google Scholar
  2. Agrons GA, Wagner BJ, Lonergan GJ et al (1997) From the archives of the AFIP. Genitourinary rhabdomyosarcoma in children: radiologicpathologic correlation. Radiographics 17: 919–937PubMedGoogle Scholar
  3. Albers P, Dieckmann KP (1998) Hodentumoren: Diagnostik and Therapie des Primärtumors. Onkologe 6: 487–493Google Scholar
  4. Albers P, Dommer K, Müller S (1998) Testicular tumors. Mortality and recurrence after inadequate therapy. Urologe A 37: 625–628PubMedGoogle Scholar
  5. Albrecht P, Bender H, Yilmaz H, Schoeneich G, Biersack H, Müller S (1999) Positron emission tomography in the clinical staging of patients with stage I and Il testicular germ cell tumors. Urology 53: 808–811Google Scholar
  6. Atkin NB, Baker MC (1995) High chromosome numbers of testicular germ cell tumours. Cancer Genet Cytogenet 88: 90Google Scholar
  7. Bajorin DF, Mazumdar M, Meyers M, Motzer RJ, Vlamis V, Lin P, Bost GJ (1998) Metastatic germ cell tumors: Modeling for Response to Chemotherapy. Clin Oncol 16: 707–715Google Scholar
  8. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. Clin Oncol 13: 1170–1176Google Scholar
  9. Bauman G, Venkatesan V, Ago C, Ratwan 1, Dar A, Vinquist W (1998) Postoperative radiotherapy for stage I/11 in seminoma: results for 212 in patients. Int J Radiat Oncol 42: 313–317Google Scholar
  10. Beard CM, Benson RC, Kelalis PP (1977) The incidence and outcome of mumps orchitis in Rochester, Minnesota 1935–1974. Mayo Clin Proc 52: 3–7PubMedGoogle Scholar
  11. Bertram KA, Bratloff B, Hodges GF, Davidson H (1991) Treatment of malignant Leydig cell tumor. Cancer 68: 2324–2329PubMedGoogle Scholar
  12. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1994) Treatment intensifica- tion in disseminated germ cell tumors. World J Urol 12: 207–218PubMedGoogle Scholar
  13. Beyer J, KramarA, Mandanas R et al. (1996) High dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. Clin Oncol 14: 2338–2345Google Scholar
  14. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1998) Salvagetherapie rezidivierter and refraktärer Hodentumoren. Onkologe 6: 541–546Google Scholar
  15. Beyer J, Schmoll Hi (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–186PubMedGoogle Scholar
  16. Birch R, Williams S, Cone A et a1. (1986) Prognostic factors for favorable out- come in disseminated germ cell tumors. Clin Oncol 4: 400–407Google Scholar
  17. Bokemeyer C, Gonnermann D, Harstrick A, Schöffski P, Schmoll HJ, Poliwoda H (1992) Metastatic Leydig-cell tumours of the testis: report of three cases. Poster, Jahrestagung der Deutschen Gesellschaft für Hämatologie and Onkologie, Berlin, 4. -7. Oktober 1992. Ann Hematol 65 [Suppl]: Abstract 39Google Scholar
  18. Bokemeyer C, Schmoll H-J (1993) Secondary neoplasms following treat- ment of malignant germ cell tumors. Clin Oncol 11: 1703–1709Google Scholar
  19. Bokemeyer C, Droz JP, Hanauske A et al. (1993) Treatment of relapsed nonseminomatous germ cell tumors with vinorelbine: a trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 16: 29–31Google Scholar
  20. Bokemeyer C, Schmoll Hi (1995) Treatment of testicular cancer and the development of secondary malignancies. Clin Oncol 13: 283–292Google Scholar
  21. Bokemeyer C, Beyer J, Metzner B et al. (1996a) Phase I l study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31–34PubMedGoogle Scholar
  22. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996b) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923–2932PubMedGoogle Scholar
  23. Bokemeyer C, Kuczyk MA, Dunn T et al. (1996c) Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. Cancer Res Clin Oncol 122: 301–306Google Scholar
  24. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. Onkologe 6: 532–540Google Scholar
  25. Bokemeyer C, Schöffski P (1999a) Sertoli-Zelltumoren. In: Schmoll H1, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie II, 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 1733–1736Google Scholar
  26. Bokemeyer C, Schöffski P (1999b) Leydig-Zelltumoren. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie II, 3. Aufl. Springer, Berlin Heidelberg New YorkTokyo, S 1737–1740Google Scholar
  27. Bokemyer C, Schöffski P (1999c) Paratestikuläres Rhabdomyosarkom. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie II. 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, 51745–49Google Scholar
  28. Bronson DL, Ritzi DM, Fraley EE, Dalton AJ (1978) Morphologic evidence for retrovirus production by epithelial cells derived from human testicular tumor metastasis. Natl Cancer Inst 60: 1305–1308Google Scholar
  29. Capelouto CC, Clark PE, Ransil BJ et al. (1995) A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 153: 981–985PubMedGoogle Scholar
  30. Carlsen E, Giwercman A, Keiding N, Skakkebaek NE (1992) Evidence for decreasing quality of semen during the past 50 years. Br Med J 305: 609–612Google Scholar
  31. Cavalli F, Monfardini Setal. (1980) Report of the international workshop on staging and treatment of testicular cancer. EurJ Cancer 16: 1367–1372Google Scholar
  32. Chaganti RSK, Rodriguez E, Mathew S (1994) Origin of adult male mediastinal germ-cell tumours. Lancet 343: 1130–1132PubMedGoogle Scholar
  33. Chaganti RSK, Murty WS, Bosl G (1996) Molecular genetics of male germ cell tumors. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Hrsg) Comprehensive Textbook of genitourinary oncology, 6th edn. pp 932–940Google Scholar
  34. Chaganti RSK, Houldsworth J (2000) Gentics and biology of adult human male germ cell tumors. Cancer Res 60: 1475–1482PubMedGoogle Scholar
  35. Chilvers CED, Forman D, Oliver RTD, Pike MC (1994) Testicular Cancer Study Group. Social, behavioural and medical factors in the aetiology of testicular cancers: results from the UK study. Br J Cancer 70: 513–520Google Scholar
  36. Christensen TB, Daugaard G, Geertsen PF et al. (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657–60PubMedGoogle Scholar
  37. Claßen J, Souchon R, Bamberg M (1998) Therapie der frühen Stadien des Seminoms. Onkologe 6: 501–510Google Scholar
  38. Clemm C, Bokemeyer C (1998) Therapie des fortgeschrittenen Seminoms. Onkologe 6: 524–531Google Scholar
  39. Clemmesen J (1968) A doubling in mortality from testis carcinoma in Copenhagen 1943–62. Acta Pathol Microbiol Scand 72: 348PubMedGoogle Scholar
  40. Collette L, Sylvester RJ, Stenning SP et al. (1999) Impact of the Treating Institution on Survival of patients with „poor-prognosis“ metastatic nonseminoma. J Natl Cancer Inst 91: 839–846PubMedGoogle Scholar
  41. Collins GM, Kim DU, Gogrone R, Richert RR, Zablow A, Breen JL (1993) Pure seminoma arising in androgen insensitivity syndrome (testicular feminization syndrome): a case report and review of the literature. Mod Pathol 6: 89–93PubMedGoogle Scholar
  42. Culine S, Theodore C, Farhat F et al. (1996) Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors. J Surg Oncol 61: 195PubMedGoogle Scholar
  43. Culine S, Kerbrat P, Bouzy J, Theodore C, Biron P, Geoffrois L et al. (1999) Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles or etoposide and cisplatin (4 EP) equivalent regimens for patients (pts) with good risk metastatic non seminomatous germ cell tumors (NSGCT)? Preliminary results of a randomzed trial. Proc Am Soc Clin On-col 18: 309aGoogle Scholar
  44. Davies JM (1981) Testicular cancer in England and Wales; some epidemiological aspects. Lancet 2: 928Google Scholar
  45. Davies T, Palmer CR, Ruja E (1996) Adolescent milk, dairy product and fruit consumption and testis cancer. Br J Cancer 74: 657–660PubMedGoogle Scholar
  46. Derigs HG, Huber C, Schmoll HJ (1994) Stadienorientierte Therapie bei nichtseminomatösen Hodentumoren. Dtsch Med Wochenschr 119: 156–164PubMedGoogle Scholar
  47. Desefano F., Annest JL, Kresnow M. (1989) Semen characteristics ofVietnam veterans. Reprod Toxicol 3: 165–173Google Scholar
  48. De Graaff WE, Ooosterhuis JW, de Jong B et al. (1992) Ploidy of testicular carcinoma in situ. Lab Invest 66: 166PubMedGoogle Scholar
  49. De Wit R, Stoter G, Sleijfer CT et al. (1998) Four cycles of BEP vs. four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78: 828–832PubMedGoogle Scholar
  50. De Wit R, Collette L, Sylvester R, de Mulder PH, Sleijer DT, ten Bokkel HWW et al. (1998) Serum alpha-seroprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78: 1350–1355PubMedGoogle Scholar
  51. De Wit R, Roberts JT, Wilkinson Petal. (2000) Final analysis demonstrating the equivalence of 3 BEP vs. 4 Cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC Phase III study. Proc Am Soc Clin Oncol: 1281Google Scholar
  52. Dieckmann KP, Klaen R, Buente S (1993a) HLA-antigenes, levis antigens and blood groups in patients with testicular germ cell tumors. Oncology 50: 252–258PubMedGoogle Scholar
  53. Dieckmann K. P, Besserer A., Loy V. (1993b) Low-dose radiation therapy for testicular intreaepithelial neoplasia. J Cancer Res Clin Oncol 119: 355–359PubMedGoogle Scholar
  54. Dieckmann KP, Loy V (1994) Management of testicular intraepithelial neoplasia. World J Urol 12: 131–135PubMedGoogle Scholar
  55. Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intreaepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14: 3126–3132PubMedGoogle Scholar
  56. Dieckmann KP, Loy V (1998) The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS 106: 13–20PubMedGoogle Scholar
  57. Dieckmann KP, Claßen J, Souchon R (2001) Therapie der testikulären intraepithelialen Neoplasie (TIN)–eine Übersicht auf der Grundlage der evidenzbasierten Medizin (EBM). Wien Klin Wochenschr 113: 7–14PubMedGoogle Scholar
  58. Donohue JP, Thornhill JA, Foster RS et al. (1994) Nonseminomatous germ-cell testicular cancer–management options and risk-benefit considerations. World J Urol 12: 170–177PubMedGoogle Scholar
  59. DonohueJP, Thornhill JA, Foster RS et al. (1995) Clinical stage B nonseminomatous germ cell testis cancer: The Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A /10: 1599–1604Google Scholar
  60. Droz JP, Kramar A, Nichols CR, Schmoll Hi, Auperin A, Harstrick A, Einhorn LH (1993) Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: assignment of prognostic groups. Proc Am Soc Clin Oncol 12: 229Google Scholar
  61. Ducatman AM (1989) Dimethylformamide, metal dyes and testicular cancer. Lancet 1: 911PubMedGoogle Scholar
  62. Duchesne GM, Stenning SP, Aass N et al. (1997) Radiotherapy after chemotherapy for metastatic seminoma–a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33: 829–835PubMedGoogle Scholar
  63. Dunn TA, Schmoll RI, Grünewald V et al. (1997a) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15: 109–114PubMedGoogle Scholar
  64. Dunn TA, Schmoll HJ, Grünewald V et al. (1997b) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. Invest New Drugs 15: 91–98PubMedGoogle Scholar
  65. Dunn T, Schmoll Hi, Rie C, Hartmann K, Casper J (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human non-seminomatous germ cell tumor (NSGCT) cell Iines. J Cancer Res Clin Oncol 124: 435–43PubMedGoogle Scholar
  66. Einhorn LH, Williams SD, Loehrer PJ et al. (1989) Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. Clin Oncol 7: 387–391Google Scholar
  67. Fizazi K, Culine S, Droz JP, Kramar A, Theodore C, Ruffle P, Le Chevalier T (1998) Primary mediastinal nonseminomatous germ cell tumors: Results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 16: 725–732PubMedGoogle Scholar
  68. Forman D, Chilvers CA (1989) A survey of sexual characteristics of yound and middle aged males in England and Wales. Br Med J 298: 1137Google Scholar
  69. Forman D, Oliver RTD, Brett AR et al. (1992) Familial testicular cancer: a report of the UK-family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 65: 255–262PubMedGoogle Scholar
  70. Forman D, Chilvers C, Oliver R, Pike M (1994) The aetiology of testicular cancer: Association with congenital abnormalities, age at puberty, infertility and exercise. Br Med J 308: 1393–1399Google Scholar
  71. Fossa SD, Ous Set al. (1985) Post-treatment fertility in patients with testicular advanced seminoma. Clin Oncol 3: 1325–1332Google Scholar
  72. Fossa SD, Aass N, Ous Set al. (1989) Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. Urol 142: 1239–1242Google Scholar
  73. Fossa SD, Oliver RT, Stenning SP et al. (1997) Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 33: 1380–1387PubMedGoogle Scholar
  74. Fossa S, Kaye S, Mead G, Cullen M, de Wit R, Bodrogi I et al. (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. Clin Oncol 16: 716–724Google Scholar
  75. Fossa SD, Bokemeyer C, Gerl A et al. (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85: 988–97PubMedGoogle Scholar
  76. Frohlich MW, Small EJ (1998) Stage nonseminomatous testis cancer: The roles of primary and adjuvant chemotherapy. Urol Clin North Am 25: 451–459PubMedGoogle Scholar
  77. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T et al. (1999) Expression of vascular endothelial growth factor 1 in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85: 1323–1330PubMedGoogle Scholar
  78. Garland FC, Gorham ED, Garland CF (1988)Testicular cancer in US Navy personnel. AmJ Epidemiol 127: 411Google Scholar
  79. Gen A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W (1995) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032Google Scholar
  80. Germa-Lluch JR, Garcia del Muro X, Tabernero JM, Sanchez M, Aparicio J, Alba E, Barnadas A (1999) BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 10: 289–293PubMedGoogle Scholar
  81. Geurts van Kessel A, Suijkerbuijk RF, Sinke RJ, Looijenga L, Oosterhuis JW, de Jong B (1993) Molecular cytogenetics of human germ cell tumors: i(12p) and related chromosomal anomalies. Eur Urol 23: 23PubMedGoogle Scholar
  82. Giwercman A, Maase H von der, Skakkebaek NE (1993a) Epidemiological and clinical aspects of carcinoma in situ of the testis. Eur Urol 23: 104–110PubMedGoogle Scholar
  83. Giwercman A, Carlson E, Keiding N, Skakkebaek NE (1993b) Evidence for increasing incidence of abnormalities of the human testis review. Ann Viron Health Perspect 101: 65–71Google Scholar
  84. Giwercman A, von der Maase H, Rorth M et al. (1994) Current concepts of radiation treatment of carcinoma in situ of the testis. World J Urol 12: 125–130PubMedGoogle Scholar
  85. Giwercman ER, Rajpert-De Meyts E, Skakkebaek NE (1996) Carcinoma in situ of the testis: A new biological concept of urological relevance and implications for detection and management. In: Vogelzang N et al. (eds) ( 1991 ) Urological oncology. Liz Weyley, pp 941–952Google Scholar
  86. Goedert JJ, Cote TR, Virgo P et al. (1998) Spectrum of AIDS-associated malignant disorders. Lancet 351: 1833–1839PubMedGoogle Scholar
  87. Gospodarowicz MK, Sturgeon JFG, Jewett MAS (1998) Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 25: 160–173Google Scholar
  88. Grocork LA, Charlton HM, Pike MC (1988) Role of foetal pituitary in cryptorchidism induced by exongenous oestrogen during pregnancy in mice. J Reprod Fertil 83: 295–300Google Scholar
  89. Grundmann E, Hermanek P, Wagner G (1997) Tumorhistologieschlüssel, 2. Aufl. ADT: Tumordokumentation in Klinik and Praxis, Bd 4. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  90. Guberman E, Usel M, Raymond L (1989) Disability, mortality and incidence of cancer among Geneva painters and electricians; a historical perspective study. Br J Ind Med 46: 16Google Scholar
  91. Harding M, Paul J, Kaye SB (1995) Does delayed diagnosis or scrotal incision affect outcome for men with nonseminomatous germ cell tumors? BritJ Urol 76: 491–494Google Scholar
  92. Harland S, Cook P, Fossa S, Norwich A, Mead G, Parkinson M et al. (1998) Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol 160: 1353–1357PubMedGoogle Scholar
  93. Harstrick A, Schmoll Hi, Wilke H et al. (1991) Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. ] Clin Oncol 9: 1549–1555Google Scholar
  94. Hartmann JT, Schmoll HJ, Kuczyk MA et al. (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous germ cell tumors. Ann Oncol 8: 531–538PubMedGoogle Scholar
  95. Heidenreich A, Bonfig R, Derschum W et al. (1995) A conservative approach to bilateral testicular germ cell tumors. J Urol 153: 10–13PubMedGoogle Scholar
  96. Heidenreich A, Vorreuther R, Braun M et al. (1995) 1st eine schnellschnittgesteuerte Therapieplanung bei testikulären Raumforderungen sinnvoll? Urologe A 34: 113Google Scholar
  97. Heidenreich A, Höltl W, Albracht W et al. (1997)Testis-preserving surgery in bilateral testicular germ cell tumors. Brit J Urol 79: 253–257Google Scholar
  98. Heidenreich A, Sesterhenn I, Mostofi A, Moul J (1998) Prognostic factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83: 1002–1011PubMedGoogle Scholar
  99. Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC (1996) Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer, 77: 2109–2116PubMedGoogle Scholar
  100. Hoff-Wanderas E, Fossa SD, Heilo A, Stenwig AE, Norman N (1990) Serum follicle stimulating hormone–predictor of cancer in the remaining testis in patients with unilateral testicular cancer. Br J Cancer 66: 315–317Google Scholar
  101. Horwich A (1991) Testicular germ cell tumors: an introductory overview. In: Norwich A (Hrsg) Testicular cancer: investigation and management. Chapman & Hall Medical, London, pp: 1–14Google Scholar
  102. Horwich A, Dearnaley DP (1992) Treatment of seminoma. Semin Oncol 19: 171–180PubMedGoogle Scholar
  103. Norwich A, Dearnaley DP, Duchesne GM et al. (1993a) Simple nontoxic treatment of advanced metastatic seminoma with Carboplatin. J Clin Oncol 7: 1150–1156Google Scholar
  104. Norwich A, A’Hearn R, Gilderslve J, Dearnaley D (1993b) Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non seminomatous germ cell cancer. Proc Am Soc Clin Oncol 12: 232Google Scholar
  105. Norwich A, Cullen M, Stenning S (1998) Primary chemotherapy after orchidectomy for stage I and Il nonseminoma. Semin Oncol 25: 154–159Google Scholar
  106. Houldsworth J, Reuter V, Bosl GJ et al. (1997) Aberrant expression of cyclin D2 is an early event in human male germe cell tumorigenesis. Cell Growth Differentiation 8: 293–299PubMedGoogle Scholar
  107. Houldsworth J, Murty VVVS, Bosl GJ, Chaganti RSK (2001) Advances in the understanding of germ cell tumour biology. In: Harnden P, Joffe JK, Jones WG (Hrsg) Germ cell tumours V. pp 23–29Google Scholar
  108. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603Google Scholar
  109. Jaeger N, Weißbach L (1990) Indikation and Ausmaß der Salvage-Lymphadenektomie beim germinalen Hodentumor. Aktuel Urol 21: 57–63Google Scholar
  110. Johnstone JA, Ross CAC, Dunn M (1972) Meningitis and encephalitis associated with mumps infection: a 10 year survey. Arch Dis Child 47: 647–651PubMedGoogle Scholar
  111. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Naylor S, Stenning SP (2001) A randomised trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRCTE18), for ECCO 2001Google Scholar
  112. Jorgensen N, MullerJ, Giwercman A, Skakkebaek NE (1990) Clinical and biological significance of carcinoma in situ of the testis. Cancer Suvr 9: 287–302Google Scholar
  113. Kattan J, Culine S, Terrier-Lacombe M-J et al. (1993) Paratesticular rhabdomyosarcoma in adult patients: 16-year experience at Institut Gustave-Roussy. Ann Oncol 4: 871–75PubMedGoogle Scholar
  114. Kaye S, Mead G, Fossa S, Cullen M, de Wit R, Bodrogi I et al. (1998) Intensive induction-sequential chemotherapy with BOPNIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692–701PubMedGoogle Scholar
  115. Klepp O, Olsson AM, Ous Set al. (1991) Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedure of the SWENOTECA project. Scand J Urol Nephrol 25: 179–190PubMedGoogle Scholar
  116. Krege S, Weißbach L, Höltl W (1998) Therapie der frühen Stadien des nichtseminomatösen Hodentumors. Onkologe 6: 511–517Google Scholar
  117. Kollmannsberger C, Beyer J, Droz JP et al. (1998) Secondary leukemia following high cumulative doses for Etoposide in patients treated for advanced germ cell tumors J Clin Oncol 16: 3386–3391Google Scholar
  118. Kollmannsberger C, Nichols C, Bamberg M et al. (2000) First-line high-dose chemotherapy +/- radiation in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 11: 553–559PubMedGoogle Scholar
  119. Kotzerke et al. (2002) Results of the 3. German Interdisciplinary Consensus Conference: Onko-PET (submitted)Google Scholar
  120. Lashley D, Lowe B (1998) A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 25: 405–423PubMedGoogle Scholar
  121. Leibovitch I, Baniel J, Foster RS et al. (1995)The clincial implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol 154: 935–939Google Scholar
  122. Leibovitch I, Little JS, Foster RS et al. (1996) Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 155: 952–954PubMedGoogle Scholar
  123. Leibovitch I, Foster R, Kopecky K et al. (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16: 261–268PubMedGoogle Scholar
  124. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. Clin Oncol 16: 2500–2504Google Scholar
  125. Looijenga LHJ (1994) Pathobiology of germ cell tumors of the adult testis. Ridderprint BV, Ridderkerk, pp: 1–160Google Scholar
  126. Mann K (1990) Tumormarker beim Hodenkarzinom. Urologe A29: 77–86PubMedGoogle Scholar
  127. MasurY, Steffens J, Ziegler M, Remberger K (1996) Leydig cell tumors of the testis–clinic and morphologic aspects. Urologe A 35: 468–471Google Scholar
  128. McCaffrey J, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and Survival. Clin Oncol 15: 2559–2563Google Scholar
  129. Mead GM (1995) International consensus prognostic classification for metastatic germ cell tumors treated with platinum-based chemotherapy: final report of the International Germ Cell Cancer Colaborative Group (IGCCCG). Proc Am Soc Clin Oncol 15: Abstr 615Google Scholar
  130. Mead GM, Stenning SP, Parkinson A et al. (1992) The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Clin Oncol 10: 85–94Google Scholar
  131. Mead GM (1995) International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14: 235, abstract 615Google Scholar
  132. Mill P, Newell G, Hohnson DE (1984) Testicular cancer associated with employment in agriculture and oil and natural gas extraction. Lancet 1: 207Google Scholar
  133. Moller H (1993) Clinics to the aetiology of testicular germ cell tumors from descriptive epidemiology. Eur Urol 23: 8–15PubMedGoogle Scholar
  134. Mostofi FK, Sobin LH (1977) Histological typing of testis tumours. In: International histological classification of tumours, No 16. World Health Organization, GeneveGoogle Scholar
  135. Mostofi FK, Sesterhenn IA (1993) Revised international histological classification of testicular tumours. Adv Biosci 91: 153–158Google Scholar
  136. Motzer RJ, BosI GJ, Heelan Retal. (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. Clin Oncol 5: 1064–1070Google Scholar
  137. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D and Bosl GJ (2000) Paclitaxel, Ifosfamide and Cisplatin Second-line therapy for patient with relapsed Testicular Germ Cell Cancer. J Clin Oncol Vol 18, 12: 2413–2418Google Scholar
  138. Muller J, Skakkebaek NE, Nielson OH (1984) Cryptorchidism and testis cancer. Cancer 54: 629–634PubMedGoogle Scholar
  139. Murty VVVS, Renault B, Falk CT, Bosl GJ, Jucherlapati R, Chaganti RSK (1996) Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12p22 in human male germ cell tumors. Genomics 35: 562–570PubMedGoogle Scholar
  140. Murty VVVS, Chaganti RSK (1998) A genetic perspective of male germ cell tumors. Semin Oncol 25: 133–144PubMedGoogle Scholar
  141. Murty VVVS, Montgmoery K, Dutta S et al. (1999) A 3-Mb high-resolution BAC, PAC contig of 12g22 encompassing the 830 kb consensus minimal deletion in male germ cell tumors. Genome Res 9: 662–671PubMedGoogle Scholar
  142. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etopsoide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. Clin Oncol 16: 1287–1293Google Scholar
  143. Nicholson PW, Harland SJ (1995) Inheritance and testicular cancer. BrJ Cancer 71: 421–426Google Scholar
  144. Nieschlag E, Behre HM (1997) Therapie mit Testosteron. In: Nieschlag E, Behre HM (Hrsg) Andrologie -Grundlagen and Klinik der reproduktiven Gesundheit des Mannes. Springer, Berlin Heidelberg New York, S 316–329Google Scholar
  145. Nieschlag E, Behre HM (1999) Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone–action, deficiency, substitution. Springer, Berlin Heidelberg New York, pp 92–114Google Scholar
  146. Oliver RTD (1987) HLA phenotype and clinical pathological behavior of germ cell tumors possible evidence for clonal evolution from semino-mas to nonseminomas. Int J Androl 10: 85–99PubMedGoogle Scholar
  147. Oliver RTD (1990) Atrophy, hormones, genes and viruses in aetiology of germ cell tumours. Cancer Sury 9: 263–268Google Scholar
  148. Oliver RTD (1996) Seventeen years experience of phase I/II studies of single agent platinum compounds as alternatives to radiation for metastatic and stage I seminoma. Proc Am Soc Clin Oncol 15: 244Google Scholar
  149. Oliver RTD (1996) Epidemiology of testis cancer In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology. Williams & Wilkins, Baltimore, pp 923–931Google Scholar
  150. Ooosterhuis JW, Looijenga LH (1993) The biology of human germ cell tumors: retrospective speculations and new perspectives. Eur Urol 23: 245Google Scholar
  151. Oosterhuis W et al. (1997) Testicular germ cell tumors. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology. Lippincott-Raven, Philadelphia New York, pp 631–42Google Scholar
  152. Oosterhuis W, van Gurp RJHLM, Rosenberg C (2001) Overexpression of the short arm of chromosome 12 is related to invasive growth of testicular seminomas and non-seminomas. In: Harnden P, Joffe JK, Jones WG (eds) Germ cell tumors, V. Springer, London Berlin Heidelberg, pp 34–37Google Scholar
  153. Ornstein DK, Dierks SM, Colberg JW (1996) Metachronous presentation of bilateral Leydig cell tumors. Urol 155: 1703Google Scholar
  154. Orozco RE, Murphy WM (1993) Carcinoma of the rete testis: Case report and review of the literature. Urol 150: 974–77Google Scholar
  155. Petersen PM, Giwercman A, Skakkebaek NE, Rorth M (1998) Gonadal function in men with testicular cancer. Semin Oncol 25: 224–233PubMedGoogle Scholar
  156. Philp T (1984) Complications of vasectomy, review of 16. 000 patients. Br J Urol 56: 745–748PubMedGoogle Scholar
  157. Pont J (1990) Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. Clin Oncol 8: 16–20Google Scholar
  158. Raja M, Oliver RTD, Badenoch D, Blandy JP (1992) Orchidopexy and transformation of seminoma to nonseminoma. Lancet 339: 930PubMedGoogle Scholar
  159. Rapley EA, Crockford GP, Teare D et al. (2000) Localization to Xp27 of a susceptibility gene for testicular germ cell tumours. Nat Genet 24: 197–200PubMedGoogle Scholar
  160. Rhomberg W, Schmoll H-J (1978) High incidence of metalworks among patients with testicular cancer detection and prevention of cancer. 2: 1737–1743Google Scholar
  161. Rhomberg W, Schmoll HJ, Schneider B (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a case-control study. Am J Ind Med 28: 79–87PubMedGoogle Scholar
  162. Robertson GS (1995) Radical orchiectomy and benign testicular condition. BrJSurg 82: 342–345Google Scholar
  163. Rosti V et al. (2002) High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 716:Google Scholar
  164. Sandberg AA, Meloni AM, Suijkerbuijk RF (1996) Reviews of chromosome studies in urological tumors. Ill. Cytogenetics and genes in testicular tumors. Urol 155: 1531–1565Google Scholar
  165. Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University Experience. Clin Oncol 16: 702–706Google Scholar
  166. Schmidberger H, Bamberg M (1995) Therapieoptionen bei testikulären Seminomen in den frühen Stadien. Strahlenther Onkol 171: 125–139Google Scholar
  167. Schmoll HJ, Harstrick A, Bokemeyer C et al. (1993) Single-agent carboplatinum for advanced seminoma: A phase II study. Cancer 72: 237–243PubMedGoogle Scholar
  168. Schmoll HJ, Harstrick A, Bokemeyer C et al. (1993) Single-agent carboplatinum for advanced seminoma: A phase II study. Cancer 72: 237–243PubMedGoogle Scholar
  169. Schmoll HJ (1997) Prognostic factors for advanced seminoma–a solid basis for clinical trials. Eur J Cancer 33: 1347–1350PubMedGoogle Scholar
  170. Schmoll HJ, Weißbach L, Bamberg M (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie 20: 164–170Google Scholar
  171. Schmoll HJ (1998) The optimal second line treatment of testicular cancer. ESMO Educ Book: 213–221Google Scholar
  172. Schmoll HJ, Beyer J (1998a) Prognostic factors in metastatic germ cell tumors. 5emin Oncol 25: 174–186Google Scholar
  173. Schmoll HJ, Beyer J (1998b) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. Onkologe 6: 518–523Google Scholar
  174. Schmoll HJ (1999a) Maligne Keimzelltumoren des Mannes In: Schmoll Hi, Höffken K, Possinger K (Hrsg. Kompendium Internistische Onkologie II, 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 1659–1732Google Scholar
  175. Schmoll Hi (1999b) Treatment of testicular tumours based on risk factors. C u rr O p i n Urol 9: 431–438Google Scholar
  176. Schmoll HJ, Krege S, Souchon R (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin. Onkologie 23: 603–613PubMedGoogle Scholar
  177. Schöffski P, Bokemeyer C, Harstrick A, Schmoll HJ (1991) Aetiologie und Epidemiologie von Keimzelltumoren. Onkologie 14 [Suppl 4]: 1Google Scholar
  178. Schultz SM, Einhorn LH, Conces DJ et al. (1989) Management of post-chemotherapy residual mass in patients with advanced seminoma. lndiana University experience. Clin Oncol 7: 1497Google Scholar
  179. Schwartz GG (2002) Hypothesis: does ochratoxin A cause testicular cancer? Cancer Causes Control 13: 91–100PubMedGoogle Scholar
  180. Sesterhenn IA, Weiss RB, Mostofi FK (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the testicular cancer intergroup study. J Clin Oncol 10: 69–78PubMedGoogle Scholar
  181. Sewell CM, Castle SP, Hull HF (1986) Testicular cancer and employment in agriculture and oil and natural gas extraction. Lancet 1: 553PubMedGoogle Scholar
  182. Sicinski P, Dohaher JL, Geng Yet al. (1996) Ciyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384: 470–474PubMedGoogle Scholar
  183. Siegert W, Beyer J, Strohscheer I et al. (1994) High dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancers. A phase I/II study. Clin Oncol 12: 1223–1231Google Scholar
  184. Siegert W, Beyer J (1998) Germ cell tumors: Dose-intensive therapy. Semin Oncol 25: 215–223PubMedGoogle Scholar
  185. Simmonds PD, Mead GM, Lee AHS et al. (1995) Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Cancer 74: 1018–1024Google Scholar
  186. Skakkebaek NE (1978) Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 2: 157PubMedGoogle Scholar
  187. Skakkebaek NE, Berthelsen JG, Müller J (1982) Carcinoma in situ of the un-descended testis. Urol Clin North Am 9: 377–385PubMedGoogle Scholar
  188. Souchon R, Schmidberger H (1998) Diagnostische Maßnahmen zur Definition des klinischen Stadiums. Onkologe 6: 494–500Google Scholar
  189. Sternberg CN (1998) The management of stage I testis cancer. Urol Clin North Am 25: 435–449PubMedGoogle Scholar
  190. Steyerberg EW, Keizer Hi, Fossa SD et al. (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic non-seminomatous germ-cell tumor. J Clin Oncol 13: 1177–1187PubMedGoogle Scholar
  191. Strader CH, Weiss NS, Daling JR (1988) Vasectomy and the incidence of testicular cancer. Am J Epidemiol 128: 56PubMedGoogle Scholar
  192. StrohmeyerT, Peter S, Hartmann M et al. (1991) Expression of the hast-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51: 1811–1816Google Scholar
  193. Swerdlow AJ, Huttly SRA, Smith PG (1988) Is the incidence of testis cancer related to trauma or temperature? Br J Ural 61: 518–521Google Scholar
  194. Swerdlow AJ (1993) The epidemiology of testicular cancer. Eur Urol 23: 35–38PubMedGoogle Scholar
  195. Swerdlow AJ (1997) Principles and practice of genitourinary oncology. Epidemiology of Testicular Cancer: 643–652Google Scholar
  196. Tarone RE, Hayes HM, Hoover RN, Rosenthal JF (1990) Service in Vietnam and risk of testicular cancer. ] Natl Cancer Inst 83: 1497–1499Google Scholar
  197. Tessler A, Catanese A (1987) Aids and germ cell tumours of testis. Urology 30: 203PubMedGoogle Scholar
  198. Teuvo L, Tammela J et. al. (1991) Intrascrotal Adenomatoid Tumors. J Urol 146: 61–65Google Scholar
  199. Thonneau P, Abell A, Larsen SB et al. (1999) Effects of pesticide exposure on time to pregnancy: results of a multicenter study in France and Denmark. ASCLEPIOS Study Group. Am J Epidemiol 150: 157–163PubMedGoogle Scholar
  200. Thornill JA, Conroy RM, Kelly DG (1988) An evaluation of predisposing factors for testis cancer in Ireland. Eur Ural 14: 429Google Scholar
  201. Tokuc R, Sakr W, Pontes J E et al. (1992) Accuracy of frozen section examination of testicular tumors. Urology 40: 521–526Google Scholar
  202. Tollerud DJ, Blattner WA, Fraser MC et al. (1985) Familial testicular cancer and urogenital developmental anomalies. Cancer 55: 1849–1854PubMedGoogle Scholar
  203. Toner C, Motzer RJ (1998) Poor prognosis germ cell tumors: Current status and future directions. Semin Oncol 25: 194–202PubMedGoogle Scholar
  204. Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. Natl Cancer Inst 89: 1429–1439Google Scholar
  205. Travis L, Andersson M, Holowarty E et al. (1999) Risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Proc Am Soc Clin Onc 18: 308a (Abstract 1185)Google Scholar
  206. Turek PJ, Lowther DN, Carroll PR (1998) Fertility issues and their management in men with testis cancer. Urol Clin North Am 25: 517–531PubMedGoogle Scholar
  207. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (1996) Comprehensive textbook of genitourinary oncology. Williams & Wilkins, BaltimoreGoogle Scholar
  208. Von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen B, Christophersen I, Hald T et al. (1986) Carcinoma in situ of the contralateral testis in patients with testicular germ cell cancer. A study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293: 1398–1401Google Scholar
  209. Warde P, Gospodarowicz MK, Panzarella T et al. (1995) Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 13: 2255–2262PubMedGoogle Scholar
  210. Warde P, von der Masse H, Norwich A, Gospodarowicz M, Panzarella T, Specht L (1998) Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 17: 309aGoogle Scholar
  211. Warde P, Jewett M (1998) Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 25: 425–433PubMedGoogle Scholar
  212. Weißbach L (1995) Organ preserving surgery of malignant germ cell tumors. Urol 153: 90–93Google Scholar
  213. Weißbach L, Bussar-Maatz R (1995) Können Risikofaktoren die Strategien im Stadium I des Nichtseminoms bestimmen? Aktuel Urol 26: 79–88Google Scholar
  214. Williams SD, Birch R, Einhorn LH et al (1987a) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440PubMedGoogle Scholar
  215. Williams SD, Stablein DM, Einhorn LH et al. (1987b) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage Il testicular cancer. N Engl J Med 317: 1433–1488PubMedGoogle Scholar
  216. Willich N (1991) Radiotherapie des Seminoms. In: Clemm (Hrsg) Urogenitaltumoren: Ergebnisse der Diagnostik, Therapie und Nachsorge, Teil 2. Zuckschwerdt, München, S 44–55Google Scholar
  217. Winfield HN (1998) Laparoscopic retroperitoneal lymphadenectomy for cancer of the testis. Urol Clin North Am 25: 469–478PubMedGoogle Scholar
  218. Wittekind C, Loy V (1998) Pathologie und pathomorphologische Diagnostik von Hodentumoren. Onkologe 6: 476–486Google Scholar
  219. World Health Organisation/WHO (1998) International histological classification of tumours. In: Mostofi FK, Sesterhenn IA (eds) Histological typing of testis tumours, 2nd edn. Springer, Berlin Heidelberg New York Tokyo, pp 1433–1488Google Scholar
  220. Zon RT, Nichols C, Einhorn LH (1998) Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16: 1294–1297PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • H. J. Schmoll

There are no affiliations available

Personalised recommendations